Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy

BACKGROUND: Duchenne muscular dystrophy (DMD) patients experience skeletal muscle degeneration, including respiratory muscles. Respiratory decline in glucocorticoid-treated DMD patients, measured by percent predicted forced vital capacity (FVC% p), is typically 5% annually in patients aged 10 to 18...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Navid, Eliopoulos, Helen, Han, Lixin, Kinane, T. Bernard, Lowes, Linda P., Mendell, Jerry R., Gordish-Dressman, Heather, Henricson, Erik K., McDonald, Craig M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2019
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598025/
https://www.ncbi.nlm.nih.gov/pubmed/30856119
http://dx.doi.org/10.3233/JND-180351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598025/
https://www.ncbi.nlm.nih.gov/pubmed/30856119
http://dx.doi.org/10.3233/JND-180351

Ejemplares similares